<DOC>
	<DOCNO>NCT02673866</DOCNO>
	<brief_summary>The hypothesis Phase 2 study least 1 dose regimen DS-1971a demonstrate clinical superiority placebo manage pain associate DPNP , generally well tolerate .</brief_summary>
	<brief_title>Study Evaluate Efficacy Safety DS-1971a Treatment Diabetic Peripheral Neuropathic Pain ( DPNP )</brief_title>
	<detailed_description />
	<mesh_term>Neuralgia</mesh_term>
	<mesh_term>Diabetic Neuropathies</mesh_term>
	<mesh_term>Pregabalin</mesh_term>
	<criteria>Male female ≥ 18 year age . Body mass index ( BMI ) ≤ 40 kg/m2 screening . Able give write informed consent . Type 1 2 diabetes . HbA1c ≥ 7.0 % &lt; 9 % screening . On stable antidiabetic medication regimen ( unchanged dose last 3 month diabetes ) prior screen ( insulin therapy acceptable ) ; recent ( i.e. , within previous 6 month ) hospitalization due noncompliance uncontrolled diabetes introduction new medication . ADPS ≥ 4 11point numeric rating scale ( NRS ) past 7 day prior randomization ( base completion least 4 daily pain diary 7day baseline period prior randomization ) . Painful distal symmetrical sensorimotor polyneuropathy diagnose least 6 month ( positive Douleur Neuropathique 4 [ DN4 ] questionnaire screening ) . Women child bear potential ( WOCBP ) must willing use doublebarrier contraception entire study . Subjects , judgement Investigator , likely compliant study . Clinically significant unstable neurologic , psychiatric , ophthalmologic , hepatobiliary , respiratory , hematologic illness unstable cardiovascular disease ( e.g. , severe hypotension , uncontrolled cardiac arrhythmia , myocardial infarction ) concurrent disease within 12 month prior screen opinion Investigator would interfere study participation assessment safety tolerability . Subjects present active cancer human immunodeficiency virus ( HIV ) infection . Creatinine clearance rate &lt; 60 mL/min . Current diagnosis epilepsy seizure disorder require chronic therapy antiepileptic . Diagnosis mononeuropathy . Subjects risk suicide define response CSSRS opinion Investigator . Note : Subjects answer `` yes '' question suicidal ideation/intent/behaviors occur within past 12 month must exclude ( CSSRS Suicide Ideation sectionQuestions 1 , 2 , 3 , 4 , 5 ; CSSRS Suicidal Behavior section , suicide behavior question ) . Such subject refer immediately mental health professional appropriate evaluation . Any major uncontrolled psychiatric disorder bipolar disorder , schizophrenia , major depression . Abnormal liver function ( aspartate aminotransferase/alanine aminotransferase ( AST/ALT ) &gt; 2.5 × upper limit normal ( ULN ) , bilirubin &gt; 1.5 ULN ) . Subjects history gout , and/or urate nephrolithiasis , and/or abnormally low serum uric acid ( low laboratory reference range men woman ) baseline . Other source pain may confound assessment selfevaluation DPNP disseminate osteoarthritis rheumatoid arthritis . Neurologic disorder unrelated diabetic peripheral neuropathy may confound assessment DPNP . Amputation low extremity ( include belowknee amputation ) due diabetes mellitus . Unable unwilling discontinue current medication chronic pain duration trial . Use concomitant medication ( i.e. , opioids , tricyclic antidepressives , and/or gamma retinoids ) may confound assessment efficacy and/or safety . Inability unwillingness discontinue prohibit concomitant medication ( see Section 5.6 ) . Abuse dependence prescription medication , street drug , alcohol within last year . Women pregnant breastfeed intend become pregnant study period . Known hypersensitivity pregabalin DS1971a and/or know treatment failure pregabalin . Subjects family member Investigator associate , colleague , employee assist conduct study ( secretary , nurse , technician ) . Subjects contact phone emergency . Participated another clinical study within 30 day prior screen receive investigational agent . Subjects unlikely comply protocol ( e.g. , uncooperative attitude , inability return subsequent visit ) and/or otherwise consider Investigator unlikely complete study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Diabetic Peripheral Neuropathic Pain ( DPNP )</keyword>
	<keyword>Diabetes</keyword>
	<keyword>Pregabalin</keyword>
	<keyword>Spontaneous Pain</keyword>
	<keyword>Hyperalgesia</keyword>
	<keyword>Allodynia</keyword>
	<keyword>Average Daily Pain Score ( ADPS )</keyword>
	<keyword>Pain Associated Sleep Interference</keyword>
</DOC>